Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Utley

Nurse Practitioner Herrin, IL Nurse Practitioner

NPI 1275905374 CMS profile 10430089

405 Rushing Dr, Herrin, IL 62948

Open in the dashboard

General payments

$7,547

552 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Utley of Herrin, IL is reported in the CMS Open Payments database as having received $7,547 across 552 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $753 43
2024 General $1,799 110
2023 General $1,413 122
2022 General $1,725 138
2021 General $1,858 139

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Utley
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Laura Utley were reported at $753. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Laura Utley Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,858 $135 $40–$426 $132
2022 $1,725 $152 $48–$470 $149
2023 $1,413 $166 $54–$529 $160
2024 $1,799 $173 $55–$556 $164
2025 $753 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,381 141 payments
  2. GlaxoSmithKline, LLC. $658 43 payments
  3. AstraZeneca Pharmaceuticals LP $650 21 payments
  4. Amgen Inc. $644 74 payments
  5. Lilly USA, LLC $487 32 payments
  6. Novo Nordisk Inc $402 28 payments
  7. Novartis Pharmaceuticals Corporation $250 17 payments
  8. Axsome Therapeutics, Inc. $249 7 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $210 13 payments
  10. Dexcom, Inc. $199 12 payments
  11. Other $2,417 164 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,547 552 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $638 41 payments
  2. UBRELVY $553 73 payments
  3. Repatha $526 65 payments
  4. BREZTRI $447 14 payments
  5. VRAYLAR $368 32 payments
  6. QULIPTA $355 36 payments
  7. FARXIGA $352 7 payments
  8. NURTEC ODT $352 23 payments
  9. Otezla $278 40 payments
  10. MOUNJARO $269 16 payments
  11. Other $6,211 401 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 102 drugs

Part D claims

4,162

Median for Nurse Practitioner: 389

Drug cost

$390,235

Median for Nurse Practitioner: $21,885

Branded share of claims

30.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 51 $53,860
Eliquis Apixaban Brand 33 $44,947
Ozempic Semaglutide Brand 41 $41,502
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 48 $40,962
Jardiance Empagliflozin Brand 22 $27,211
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 33 $24,334
Linzess Linaclotide Brand 17 $22,683
Trijardy Xr Empaglifloz/Linaglip/Metformin Brand 19 $20,461
Trulicity Dulaglutide Brand 14 $13,434
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 20 $9,317

The 10 drugs with the highest cost, of 102 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $190
$190 — —
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $120
$120 — —
BRIXADI
  • Braeburn Inc. $107
$107 — —
MOUNJARO
  • Lilly USA, LLC $83
$83 51 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $82
$82 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

552 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record